Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
- Journal:
- Clinical Infectious Diseases
- Published:
- DOI:
- 10.1093/cid/ciaf548
- Affiliations:
- 7
- Authors:
- 11
| Institutions | Authors | Share |
|---|---|---|
| Pfizer, United States of America (USA) | 0.82 | |
| Pfizer Ltd., United Kingdom (UK) | 0.09 | |
| Pfizer Italia srl, Italy | 0.09 |